TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06604689

Intervention type: DRUG
Intervention: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Description: EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)

Intervention type: DRUG
Intervention: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Description: EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)
Study: NCT06598202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop
Description: Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop
Description: Exosomes placebo
Study: NCT06666985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITM + Usual Care
Description: The participants allocated to this group will receive ITM (Intrathecal Morphine) in addition to usual care with opioid-based PCA(Patient-Controlled Analgesia). ITM consists of an intrathecal injection of 300 micrograms (0.3mg) of preservative-free morphine.Usual care involves postoperative analgesia with opioid-based PCA without postoperative continuous infusion of opioids. No other drugs other than opioids are allowed in the PCA.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham ITM + Usual Care
Description: The sham ITM mimics the ITM procedure, but the dura is not breached.
Study: NCT06666192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Screening
Description: Undergo cancer screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in discussions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in discussions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in discussions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Activity
Description: Receive coaching calls

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Participate in focus group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Care Delivery
Description: Integrate new activities into usual clinic processes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Care Delivery
Description: Integrate new activities into usual clinic processes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: Promote screening and wellness visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Participate in educational sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Participate in early wave MLI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Participate in late wave MLI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Risk Assessment
Description: Incorporate risk assessments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation
Description: Implement MLI

Intervention type: OTHER
Group type: OTHER
Intervention: Informational Intervention
Description: Review MLI materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive educational online materials

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Participate in interview
Study: NCT05597722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital cognitive behavioral intervention-RxWell
Description: RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine-Dextroamphetamine
Description: Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
Study: NCT06666192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outreach
Description: Receive outreach activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Receive access to CHW

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Receive access to CHW
Study: NCT05825742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral health instructions
Description: Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard oral health instructions
Description: Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
Study: NCT06520098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib, Acalabrutinib, Zanubrutinib
Description: IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib, Acalabrutinib, Zanubrutinib
Description: IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors
Study: NCT06588582

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water Temperature Variation - WW
Description: Participants are assigned to warm water temperature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Temperature Variation - CW
Description: Participants are assigned to cold water temperature and are video recorded.
Study: NCT06666699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS access device
Description: The intervention involves the use of an EUS access device to gain access to the bile duct via hepaticogastrostomy.
Study: NCT05876039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial remifentanil effect-site concentration
Description: Different initial remifentanil effect-site concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initial remifentanil effect-site concentration
Description: Different initial remifentanil effect-site concentration
Study: NCT06597942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: Sham coil placed in same location and set with same parameters as active treatment coil. However, this device will not output active treatment and scalp electrodes will mimic the sensation of rTMS for the participant.
Study: NCT06666192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06666595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium dental implant (Conical SPI, Vitronix, Italy), Medical device that interfaces with the jawbone to support a dental prosthesis.
Description: Placement of titanium dental implant to retain and support Kennedy class 1 removable partial denture (RPD).The implant fuses with the bone through a process called osseointegration.
Study: NCT06676982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T
Description: All subjects were intravenous administrated with CNCT19 CAR-T.
Study: NCT06619691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine motor skills
Description: Only intervention
Study: NCT06715124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3544
Description: QTX3544 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3544
Description: QTX3544 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3544
Description: QTX3544 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3544
Description: QTX3544 will be administered at protocol defined dose.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.
Study: NCT06538831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet N-P-
Description: Low in saturated fatty acids (SFAs), free sugar and sodium; Low in ultra-processed foods (UPFs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet N+P-
Description: Rich in SFAs, free sugar and sodium; Low in UPFs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet N-P+
Description: Low in SFAs, free sugar and sodium; High in UPFs
Study: NCT06715124

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.
Study: NCT06723535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days
Study: NCT06734312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Fundal Mucosal Ablation (GFMA)
Description: Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy
Study: NCT06740357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor response monitoring program
Description: three steps of tumor response evaluation (STEP 1 at 2 months, STEP 2 at 4 months, STEP 3 at 6 months after completion of neoadjuvant treatment): STEP 1: digital rectal examination, pelvic MRI, rectoscopy, TAP scan STEP 2: DRE, pelvic MRI, rectoscopy STEP 3: DRE, pelvic MRI, rectoscopy, TAP or PET scan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard evaluation of tumor response
Description: Assessment at 2 months (+/- 7 days) after neoadjuvant treatment: digital rectal exam, pelvic MRI, rectoscopy, TAP scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making
Description: At each stage of the monitoring program and depending on the clinical and oncological results, the decision to preserve the rectum will be discussed with the patient according to a shared-decision program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision-making according to national recommendations
Description: The decision to preserve the rectum is based on assessment at 2 months after completion of neoadjuvant treatment (standard of care since the GRECCAR2 trial).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up
Description: Every 3 months for 2 years, then every 6 months for the third year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Every 3 months for 2 years, then every 6 months for the third year
Study: NCT06762886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Description: The case was lying back in a comfortable position on the stationary bike ergometer when the exercise test was conducted. The exercise test began with a 3-minute warm-up session of unloaded cycling on a cycle ergometer, and then progressed at a rate of 10 W per minute up to the subject's threshold. After cycling for 30 W to warm up, the intensity was raised by 15 W every 60 seconds until fatigue, after which the individuals cycled for 30 W to cool down. This treatment protocol was administered to each patient 3 times/week for a total of 15 minutes of treatment, broken into intervals of two to three minutes each.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: The laser probe was administered using the contact approach on the dorsal midline, in the depression below the spinous process of C7 at Governor Vessel, with the patient seated in a chair with back support (GV - 14 Dazhui). The primary power switch was activated. The following settings were used for applying laser puncture: 5 mW, the maximum average power. Type of laser: gallium arsenide (Ga-As), 904 nm wavelength, 5 kHz maximum repetition rate - Program: Maintaining programs for people who had their neck lymph nodes removed and have a low leukocyte count, up to 30 J/cm2 of energy, a 2 J/cm2 energy density, and protective glasses were required to prevent irreversible eye injury from either direct or indirect laser exposure. The treatment took place for 15 minutes.
Study: NCT06764316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 3547926
Description: antibody conjugate with actinium-225 label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 3547922
Description: antibody conjugate without actinium-225 label as preinjection
Study: NCT06760026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision
Description: 2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subdermal suture
Description: wound closure with subdermal sutures using 2-0 nylon thread, under the same evaluation scheme
Study: NCT06762795

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genome sequencing
Description: Neonates enrolled in this study will undergo genome sequencing with parental controls as applicable.
Study: NCT06762964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin tablet
Description: Patient will take a 10mg tablet of Dapagliflozin once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Patient will take 10mg placebo tablet once daily for 24 weeks
Study: NCT06764784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freehand Implant Surgery
Description: This intervention involves implant placement performed manually by the surgeon without the use of specialized guides. The procedure relies on the surgeon's clinical judgment and experience to determine the implant's positioning, angulation, and depth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilot-Drilled Implant Surgery
Description: This intervention utilizes a pilot drill to create an initial guide hole for the implant. The pilot-drilled pathway improves accuracy while still allowing the surgeon flexibility during the procedure. The final implant is placed following sequential drilling.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fully Guided Implant Surgery
Description: This intervention employs computer-aided surgical templates created from preoperative imaging data, such as CBCT scans. These guides ensure precise implant positioning, angulation, and depth based on preoperative planning. The approach minimizes variability and enhances accuracy.
Study: NCT06763692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFU Neuromodulation
Description: Subjects will undergo a single LIFU of the target brain region
Study: NCT06763328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06763328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive standard of care healthy diet and exercise handouts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive standard of care healthy diet and exercise handouts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metformin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06764225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-sodium substitute salt
Description: This study specifically customized sodium reducing substitute salts with a sodium chloride content not exceeding 62% and without the addition of potassium chloride.
Study: NCT06668714

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + mixed meal
Description: Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo + mixed meal
Description: Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + mixed meal
Description: Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR
Study: NCT04904770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoop stretcher
Description: Already included in arm/group description

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum mattress
Description: Already included in arm/group description
Study: NCT06454617

Intervention type: OTHER
Intervention: Phantom
Description: The patients will be simultaneously scanned with a QCT phantom
Study: NCT06325423

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy
Description: platinum-based chemotherapy before radical cystectomy or bladder preservation
Study: NCT05662384

Intervention type: OTHER
Intervention: No intervention is planned
Description: Observational study, no intervention
Study: NCT04384016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skyvaricella Injection
Description: The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skyvaricella Injection
Description: The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection.
Study: NCT05279456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-CpG55.2 adjuvanted recombinant spike protein
Description: recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-CpG55.2 adjuvanted recombinant spike protein
Description: recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
Study: NCT06668714

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lactate + mixed meal
Description: Lactate (140 mL lactate drink = 25 g D/L-lactate bound to Na) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = LAC The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.
Study: NCT05272891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: audio book app
Study: NCT06363422

Intervention type: PROCEDURE
Intervention: Epicanthoplasty
Description: Patients with unsatisfied blepharoplasty underwent epicanthoplasty in our center
Study: NCT06668714

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Lactate + mixed meal
Description: Lactate (140 mL lactate drink = 25 g D/L-lactate bound to Na) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = LAC The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET-scan
Description: Dynamic whole-body PET scan.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-scan
Description: Dynamic whole-body PET scan.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET-scan
Description: Dynamic whole-body PET scan.